Discover

IRIX
IRIDEX Corporation
1.17
2 x 0.85
2 x 1.49
bid
ask
+
0.02
2.18%
2 @ 04:00 PM
1.17 +0.00 (0.00%)
Ytd2.63%
1y31.46%
1.15
day range
1.19
0.87
52 week range
1.65
Open1.18Prev Close1.15Low1.15High1.19Mkt Cap20.37M
Vol9.67KAvg Vol252.60KEPS-0.19P/EN/AForward P/E-5.85
Beta0.81Short Ratio7.38Inst. Own20.06%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1850-d Avg1.09200-d Avg1.161yr Est2.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-122024-090-0.12N/AN/A
2024-08-082024-06-0.12-0.16-0.04-33.33%
2024-05-142024-03-0.12-0.21-0.09-75.00%
2024-03-262023-12-0.05-0.18-0.13-260.00%
2023-11-142023-09-0.13-0.110.0215.38%
2023-08-102023-06-0.11-0.17-0.06-54.55%
Upgrade / Downgrade
DateFirmActionFromTo
2024-05-15StifelUpgradeHoldHold
2022-08-26StifelDowngradeBuyHold
2021-05-12Roth CapitalUpgradeBuy
2021-03-03Roth CapitalUpgradeBuy
2021-01-13Roth CapitalUpgradeBuy
2020-05-12StifelUpgradeBuy
Profile
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Insider Holder
DateNameRelationQuantityDescription
2023-06-13DEVI NANDINIDirector77.16KStock Award(Grant)
2023-06-13GROVE ROBERT EARLEDirector160.10KStock Award(Grant)
2023-06-13HUSS BEVERLY ADirector66.74KStock Award(Grant)
2023-06-13LUDLUM KENNETH E.Director101.71KStock Award(Grant)
2024-11-06MERCER PATRICKChief Executive Officer393.24KStock Award(Grant)
2023-06-13SHUDA SCOTT ADirector108.07KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Paragon Associates & Paragon Associates Ii Joint Venture1000.00K1.58M6.01%
2024-09-29Vanguard Group Inc561.10K886.53K3.37%
2024-09-29AMH Equity Ltd.501.12K791.77K3.01%
2024-09-29Renaissance Technologies, LLC397.36K627.83K2.39%
2024-09-29Geode Capital Management, LLC131.17K207.25K0.79%
2024-09-29ARS Investment Partners, LLC113.57K179.43K0.68%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Vanguard Total Stock Market Index Fund376.94K595.57K2.27%
2024-09-29Vanguard Extended Market Index Fund164.11K259.30K0.99%
2024-09-29Bridgeway Funds Inc-Ultra Small Company Market Fund75.00K118.50K0.45%
2024-10-30Fidelity Extended Market Index Fund71.10K112.33K0.43%
2024-10-30iShares Micro Cap ETF33.60K53.09K0.20%
2024-10-30Fidelity Series Total Market Index Fund16.07K25.38K0.10%